anti-doping testing comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-19. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
The new middle class, led by those who agitated against the slave trade, in the city began to engage in charitable works. Notable were Mary Carpenter, who founded ragged schools and reformatories, and George Müller who founded an orphanage in 1836. Badminton School was started in Badminton House, Clifton in 1858 and Clifton College was established in 1862. University College, the predecessor of the University of Bristol, was founded in 1876 and the former Merchant Venturers Navigation School became the Merchant Venturers College in 1894. This later formed the nucleus of Bristol Polytechnic, which in turn became the University of the West of England. The Bristol Riots of 1831 took place after the House of Lords rejected the second Reform Bill. Local magistrate Sir Charles Wetherell, a strong opponent of the Bill, visited Bristol to open the new Assize Courts and an angry mob chased him to the Mansion House in Queen Square. The Reform Act was passed in 1832 and the city boundaries were expanded for the first time since 1373 to include "Clifton, the parishes of St. James, St. Paul, St. Philip, and parts of the parishes of Bedminster and Westbury". The parliamentary constituencies in the city were revised in 1885 when the original Bristol (UK Parliament constituency) was split into four. Bristol lies on one of the UK's lesser coalfields, and from the 17th century collieries opened in Bristol, and what is now North Somerset and South Gloucestershire.
=== ColdFusion and Java === The standard ColdFusion installation allows the deployment of ColdFusion as a WAR file or EAR file for deployment to standalone application servers, such as Macromedia JRun, and IBM WebSphere. ColdFusion can also be deployed to servlet containers such as Apache Tomcat and Mortbay Jetty, but because these platforms do not officially support ColdFusion, they leave many of its features inaccessible. As of ColdFusion 10 Macromedia JRun was replaced by Apache Tomcat. Because ColdFusion is a Java EE application, ColdFusion code can be mixed with Java classes to create a variety of applications and use existing Java libraries. ColdFusion has access to all underlying Java classes, supports JSP custom tag libraries, and can access JSP functions after retrieving the JSP page context (GetPageContext()). Prior to ColdFusion 7.0.1, ColdFusion components could only be used by Java or .NET by declaring them as web services. However, beginning in ColdFusion MX 7.0.1, ColdFusion components can now be used directly within Java classes using the CFCProxy class. Recently, there has been much interest in Java development using alternate languages such as Jython, Groovy and JRuby. ColdFusion was one of the first scripting platforms to allow this style of Java development.
It has been proposed that ubiquitin is the slowest-evolving protein identified to date. Ubiquitin contains seven lysine residues to which another ubiquitin can be ligated, resulting in different types of polyubiquitin chains. Chains in which each additional ubiquitin is linked to lysine 48 of the previous ubiquitin have a role in proteasome targeting, while other types of chains may be involved in other processes.
On 9 May 2024, control Judge Juan Manuel Fernández López rejected Agüero's appeals against the prosecution's petition to take her to trial, and ordered that she stand trial on five counts of aggravated murder, as well as eight other counts of attempted murder. Along with Agüero, Judge Fernández López also ordered that 10 officials face trial at the same courtroom where Agüero will be tried. The trial against Brenda Agüero and the other ten defendants commenced on 6 January 2025. Agüero denied committing the crimes during her first testimony, saying that there is "no possibility that harming another person crosses my mind; much less a child." On 22 January, the mother of one of the babies who decompensated (a baby girl named Isabella) testified that she saw Agüero injecting her baby while the little girl was in the cradle. The woman said that the baby cried as Agüero injected her shortly before decompensating. On 30 January, medical professionals testified at the trial, saying that the babies did not die from a natural cause, and confirmed that the levels of potassium or insulin in their bodies were injected deliberately. On 4 February, a neonatal doctor testified that during her shift on 6 June 2022, when two healthy babies died without presumptive cause, she saw Brenda Agüero with a baby in her arms, and that Agüero told her that the baby "was not well". The baby later died from a serious case of bradycardia. The doctor also confirmed that the nature of the deaths of these healthy babies raised suspicions from the doctors who attempted to resuscitate them.
Sources: en.wikipedia.org
== See also == Chromatophore (the pigment cell type found in poikilotherm animals) Eye color Mole (skin marking) Tanning activator List of distinct cell types in the adult human body List of human cell types derived from the germ layers
The international community refused to accept the validity of any agreement which did not incorporate the main nationalist parties. The British government (then led by the recently elected Margaret Thatcher) issued invitations to all parties to attend a peace conference at Lancaster House. These negotiations took place in London in late 1979. The three-month-long conference almost failed to reach conclusion, due to disagreements on land reform, but resulted in the Lancaster House Agreement. UDI ended, and Rhodesia temporarily reverted to the status of a British colony (the 'Colony of Southern Rhodesia'). As per the agreement, Lord Soames became governor with full legislative and executive powers. The Lancaster House Agreement further provided for a ceasefire which was followed by an internationally supervised general election, held in February 1980. ZANU led by Robert Mugabe won this election, some alleged, by terrorising its political opposition, including supporters of ZAPU, through former insurgents that had not confined themselves to the designated guerrilla assembly points, as stipulated by the Lancaster House Agreement. The observers and Soames were accused of looking the other way, and Mugabe's victory was certified. Nevertheless, few could doubt that Mugabe's support within his majority Shona tribal group was extremely strong. The Rhodesian military seriously considered mounting a coup against a perceived stolen election ("Operation Quartz") to prevent ZANU from taking over the country.
== List of immunohistological markers for canine histiocytic diseases == Cutaneous histiocytoma = Langerhans cells: CD1+, CD11c+, MHCII+, CD86+, E-cad+, Langerin+, CD14-, Thy1- Reactive histiocytosis = Interstitial/dermal dendritic cells: CD1+, CD11b+, CD11c+, MHCII +, CD86+, Thy1+, CD4+, CD14-, E-cad- Histiocytic sarcoma complex = Dendritic cells (interdigitating or perivascular?): CD1+, CD11c+, MHCII+, E-cad-, Thy1-, CD4- Macrophages (for example in haemophagocytic syndrome): CD11d+, CD14+, MHCII+/-, CD1-, CD86-, Thy1-, E-cad-.
In its pharmaceutical form, most overdose deaths attributed solely to fentanyl occur at serum concentrations at a mean of 0.025 μg/mL, with a range 0.005–0.027 μg/mL. In contexts of poly-substance use, blood fentanyl concentrations of approximately 0.007 μg/mL or greater have been associated with fatalities. Over 85% of overdoses involved at least one other drug, and there was no clear correlation showing at which level the mixtures were fatal. The dosages of fatal mixtures varied by over three magnitudes in some cases. Naloxone (sold under the brand name Narcan) can completely or partially reverse an opioid overdose. In July 2014, the Medicines and Healthcare products Regulatory Agency (MHRA) of the UK issued a warning about the potential for life-threatening harm from accidental exposure to transdermal fentanyl patches, particularly in children, and advised that they should be folded, with the adhesive side in, before being discarded. The patches should be kept away from children, who are most at risk from fentanyl overdose. In the US, synthetic opioids (including fentanyl) were detected in over 29,000 deaths in 2017, a large increase over the previous four years.
=== Nutrient sensing === The hexosamine biosynthetic pathway's product, UDP-GlcNAc, is utilized by OGT to catalyze the addition of O-GlcNAc. This pathway integrates information about the concentrations of various metabolites including amino acids, carbohydrates, fatty acids, and nucleotides. Consequently, UDP-GlcNAc levels are sensitive to cellular metabolite levels. OGT activity is in part regulated by UDP-GlcNAc concentration, making a link between cellular nutrient status and O-GlcNAc. Glucose deprivation causes a decline in UDP-GlcNAc levels and an initial decline in O-GlcNAc, but counterintuitively, O-GlcNAc is later significantly upregulated. This later increase has been shown to be dependent on AMPK and p38 MAPK activation, and this effect is partially due to increases in OGT mRNA and protein levels. It has also been suggested that this effect is dependent on calcium and CaMKII. Activated p38 is able to recruit OGT to specific protein targets, including neurofilament H; O-GlcNAc modification of neurofilament H enhances its solubility. During glucose deprivation, glycogen synthase is modified by O-GlcNAc which inhibits its activity.
Sources: en.wikipedia.org
=== Economics === In the US, generic methadone tablets are inexpensive, with retail prices ranging from $0.25 to $2.50 per defined daily dose. Methadone maintenance clinics in the US may be covered by private insurance, Medicaid, or Medicare. Medicare covers methadone under the prescription drug benefit, Medicare Part D, when it is prescribed for pain, but not when it is used for opioid dependence treatment because it cannot be dispensed in a retail pharmacy for this purpose. In California methadone maintenance treatment is covered under the medical benefit. Patients' eligibility for methadone maintenance treatment is most often contingent on them being enrolled in substance abuse counseling. People on methadone maintenance in the US either have to pay cash or if covered by insurance must complete a pre-determined number of hours per month in therapeutic groups or counseling. The United States Department of Veteran's Affairs (VA) Alcohol and Drug Dependence Rehabilitation Program offers methadone services to eligible veterans enrolled in the VA health care system. Methadone maintenance treatment (MMT) cost analyses often compare the cost of clinic visits versus the overall societal costs of illicit opioid use. A preliminary cost analysis conducted in 2016 by the US Department of Defense determined that methadone treatment, which includes psychosocial and support services, may cost an average of $126.00 per week or $6,552.00 per year.
Prior to the widespread introduction of the vaccine in the United States in 1995 (1986 in Japan and 1988 in Korea), there were around 4,000,000 cases per year in the United States, mostly in children, with typically 10,500–13,000 hospital admissions (range, 8,000–18,000), and 100–150 deaths each year. Most of the deaths were among young children. During 2003, and the first half of 2004, the CDC reported eight deaths from varicella, six of whom were children or adolescents. These deaths and hospital admissions have substantially declined in the US due to vaccination, though the rate of shingles infection has increased as adults are less exposed to infected children (which would otherwise help protect against shingles). Ten years after the vaccine was recommended in the US, the CDC reported as much as a 90% drop in chickenpox cases, a varicella-related hospital admission decline of 71% and a 97% drop in chickenpox deaths among those under 20. Vaccines are less effective among high-risk patients, as well as being more dangerous because they contain attenuated live viruses. In a study performed on children with an impaired immune system, 30% had lost the antibody after five years, and 8% had already caught wild chickenpox in those five years.
The first patch for the Xbox 360 version was released about two weeks after release to fix some of the game stability issues players had reported. The patch was found to introduce more problems to the game for some users, including occasional freezes, bad framerates, and audio-related issues, though methods to resolve these issues through the console's cache system were outlined by Irrational Games. In December 2007, a common patch was released for both the Xbox 360 and Windows version. The patch included additional content such as new Plasmids, new achievements for the Xbox 360 version, and a FOV lock that allowed widescreen players a wider field of view without losing vertical information. The patch also added in an option to disable the use of Vita-Chambers, a feature requested by players to make the game more challenging, as well as an achievement to complete the game at its hardest setting without using a Vita-Chamber. In 2014, 2K Games released a DRM-free version of BioShock in the Humble 2K Bundle, followed by DRM-free releases on GOG in 2018.
=== Algae-derived fibers (Alginate) === Alginate is a polysaccharide generated by brown algae, seaweed and specific species of bacteria. Bacteria and seaweed alginate differ in composition, modifications, molecular mass, viscoelasticity, and polydispersity. These unique qualities lead to a wide range of applications, including alginate's development of nanoparticles, nanotubes, microspheres, and microcapsules. Furthermore, the different types of sponges, hydrogels, foams, elastomers, and fibers that can be created with its growth and processing. It is widely employed in many facets of industrial fabrication. Alginate is commonly employed as a gelling agent, thickener, and stabilizer in a large variety of food products. Its ability to form gels under mild conditions makes it particularly useful for encapsulating flavors, vitamins, and other active ingredients. It is also used to develop hydrogels, printing pastes and sizing agents in biomedical, textile, cosmetic and agricultural industries. In the textile industry specifically, textile coatings, binders and finishes are the bulk of what alginate is used for, rather than formulating threads itself it reinforces the strength of other materials.
To commemorate the occasion, the airline named the McDonnell Douglas MD-11 operating the inaugural flight Elvis 1 and gave each passenger gifts, among them a small bottle of Jack Daniel's whiskey. In preparation for the flight, the airport had constructed a new customs facility. In 1997, Northwest acquired Express Airlines I, a regional carrier that operated under the Northwest Airlink brand, and shifted its headquarters to Memphis. The airport served 11.8 million travelers in 2000. The Memphis–Shelby County Airport Authority expanded the facilities. The passenger terminal was enlarged five times between 1986 and 1999. Northwest and the airport authority worked together on the fifth project. They added 15 gates to Concourse A for Express I's new 50-seat Bombardier CRJs. Other upgrades included a post-security corridor linking Concourses B and C, a new lounge, and faster ticket counters. A third parallel runway opened in 1997. Three years later, the middle runway was rebuilt and lengthened to 11,120 feet (3,390 m). Dubbed the World Runway, it enabled KLM to take off from Memphis with a full cabin in hot conditions and FedEx to carry more cargo.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.